Pasithea Therapeutics (KTTA) Stock: Buy, Sell, or Hold?
KTTA - Pasithea Therapeutics Corp. Common Stock
$0.49
0.00 (-0.79%)
▼
5d:
-4.79%
30d:
-13.13%
90d:
-11.04%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When KTTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KTTA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KTTA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KTTA is currently trading at $0.49, which is considered oversold relative to its 30-day fair value range of $0.50 to $0.57.
Technical Outlook: Technically, KTTA is in a downtrend. Immediate support is located at $0.45, while resistance sits at $0.55.
Market Sentiment: KTTA scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.00 (+513.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KTTA is in a downtrend. Immediate support is located at $0.45, while resistance sits at $0.55.
Market Sentiment: KTTA scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.00 (+513.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.50 -
$0.57
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (88/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 513.4% below Wall St target ($3.00)
- CAUTION: Bottoming setup, but lagging the sector by 28% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$0.50 -
$0.57
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.45
Resistance Level
$0.55
Current Trend
Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.06
Wall Street Target
$3.00
(+513.4%)
Revenue Growth (YoY)
1498.1%
Share & Embed Analysis
Last updated: October 02, 2026 3:04 AM ET
Data refreshes hourly during market hours. Next update: 4:04 AM
Data refreshes hourly during market hours. Next update: 4:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KTTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 58 HOLD |
|
IMCR
Immunocore Holdings Ltd |
STRONG BUY
17 analysts |
$63 | 74 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$21 | 52 HOLD |
